Contact information
matthew.wood@paediatrics.ox.ac.uk
01865 272419
01865 282840
Louise Gillane
mjaw-pa@paediatrics.ox.ac.uk
Research groups
Matthew Wood
Professor of Neuroscience
Matthew Wood graduated in Medicine from the University of Cape Town in 1987, working in clinical Neuroscience before gaining a doctorate in Physiological Sciences from the University of Oxford in 1993. He is currently University Lecturer, and Fellow and Tutor in Medicine and Physiology at Somerville College.
Matthew’s research is in field of gene therapy for degenerative disorders of the nervous system and muscle. The main focus is the investigation of novel therapeutic approaches utilising short nucleic acids to target messenger RNA. Targeting RNA has the potential to allow modification of the target transcript, reprogramming of endogenous genetic defects or the targeting of specific disease alleles, all the while maintaining endogenous regulation of the target gene. Current work is investigating the potential of single-stranded antisense oligonucleotides for the modification of mRNA splicing, for example in Duchenne muscular dystrophy. In addition, the potential of double-stranded RNA for gene silencing, known as RNA interference (RNAi), is being investigated for the silencing of target genes and mutant alleles both in muscle and in the nervous system. In particular, RNAi has great potential as a future therapeutic agent for currently untreatable neurodegenerative disorders such as Parkinson’s disease.
Key publications
-
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
Journal article
Alvarez-Erviti L. et al, (2011), Nat Biotechnol, 29, 341 - 345
Recent publications
-
Erratum: Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency (Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency (2013) 2 (1–10), (S2162253116301834), (10.1038/mtna.2013.51))
Journal article
Yin HF. et al, (2020), Molecular Therapy - Nucleic Acids, 22
-
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Journal article
Marsh S. et al, (2020), Mol Ther
-
Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle.
Journal article
Conceição M. et al, (2020), Biomaterials, 266
-
Mutation-independent proteomic signatures of pathological progression in murine models of Duchenne muscular dystrophy.
Journal article
van Westering TLE. et al, (2020), Mol Cell Proteomics
-
An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress.
Journal article
Feneberg E. et al, (2020), Neurobiol Dis